Actinium Pharmaceuticals, Inc.
ATNMAMEXHealthcare● Active
$1.06
$-0.02(-1.85%)
Market Cap$33257494
P/E Ratio—
52W High$1.945
52W Low$0.952
Actinium Pharmaceuticals, Inc. (ATNM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ATNM · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.09M | $0.00M | $0.08M | $1.03M | $1.14M |
| Cost of Revenue | $0.00M | $0.81M | $0.00M | $0.00M | $0.52M |
| Gross Profit | $0.09M | ($0.81M) | $0.08M | $1.03M | $0.62M |
| Gross Margin %(computed) | 100.00% | — | 100.00% | 100.00% | 54.20% |
| Operating Expenses | |||||
| R&D Expenses | $21.12M | $30.05M | $38.67M | $23.14M | $17.51M |
| G&A Expenses | $15.21M | $12.08M | $13.33M | $12.00M | $0.00M |
| Total Operating Expenses | $36.34M | $41.31M | $52.00M | $35.13M | $25.58M |
| Operating Income | ($36.25M) | ($42.12M) | ($51.92M) | ($34.10M) | ($24.96M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $2.36M | $3.88M | $3.10M | $1.09M | $0.19M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($33.89M) | ($38.24M) | ($48.82M) | ($33.02M) | ($24.77M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($33.89M) | ($38.24M) | ($48.82M) | ($33.02M) | ($24.77M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.09 | $-1.27 | $-1.83 | $-1.37 | $-1.20 |
| Wtd Avg Shares | 31.20M | 30.07M | 26.60M | 24.14M | 20.57M |
| EBITDA | ($35.43M) | ($37.43M) | ($51.13M) | ($33.41M) | ($24.25M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Actinium Pharmaceuticals, Inc. data
About Actinium Pharmaceuticals, Inc. (ATNM) Income Statement
Actinium Pharmaceuticals, Inc. (ATNM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ATNM reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.03B) — a net profit margin of -37652.22%.
Frequently asked questions
ATNM · 4 questionsActinium Pharmaceuticals, Inc. (ATNM) reported revenue of $0.00B for 2025, up —% year-over-year.
ATNM revenueATNM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09